



2022 American Society of Hematology (ASH) Annual Conference

TAKEDA SPONSORED ABSTRACTS

ONCOLOGY

ABSTRACT #

TITLE

SESSION

CHRONIC MYELOID LEUKEMIA

[ABSTRACT
620](#)

Three-year Update from the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

ORAL PRESENTATION

Chronic Myeloid Leukemia: Clinical and Epidemiological: Longer Term Response, TFR, Pregnancy, and Disparities

December 11, 2022
4:45–6:15 P.M. CT

Location: Ernest N. Morial Convention Center, 388-390



[ABSTRACT
3009](#)

Molecular Response of $\leq 10\%$ BCR::ABL1^{IS} is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 OPTIC Trial

POSTER PRESENTATION

Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

December 11, 2022
6:00–8:00 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D



[ABSTRACT
3024](#)

Chronic-Phase Chronic Myeloid Leukemia Times to Death by Disease Support Tyrosine Kinase Inhibitor Dose Reductions When BCR::ABL1 Level Is $< 1\%$ and Decreasing

POSTER PRESENTATION

Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

December 11, 2022
6:00–8:00 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D

HODGKIN LYMPHOMA

[ABSTRACT
1616](#)

Population Pharmacokinetics (PPK) and Exposure-Response to Support Body Surface Area (BSA)-Based Dosing of Brentuximab Vedotin in Pediatric Patients with Advanced-Stage Newly-diagnosed Hodgkin Lymphoma (HL)

POSTER PRESENTATION

Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I

December 10, 2022
5:30–7:30 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D



MULTIPLE MYELOMA

[ABSTRACT
4491](#)

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

POSTER PRESENTATION

Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III

December 12, 2022
6:00–8:00 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D



ABSTRACT # TITLE SESSION

MULTIPLE MYELOMA (CONTINUED)**[ABSTRACT
565](#)**

Final Results from the First-In-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

ORAL PRESENTATION

Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Novel Drugs and Optimized Approaches in Myeloma

December 11, 2022
12:00-1:30 P.M. CT

Location: Ernest N. Morial Convention Center, New Orleans Theater C

**[ABSTRACT
1859](#)**

Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from The INSIGHT MM Global, Prospective, Observational Study

POSTER PRESENTATION

Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I

December 10, 2022
5:30-7:30 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D

**[ABSTRACT
1878](#)**

Comparative Effectiveness of Lenalidomide/ Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined by Cytogenetic Risk

POSTER PRESENTATION

Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I

December 10, 2022
5:30-7:30 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D

**[ABSTRACT
3255](#)**

In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

POSTER PRESENTATION

Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II

December 11, 2022
6:00-8:00 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D

**[ABSTRACT
1880](#)**

Effectiveness and safety of Ixazomib in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma in a real-life population in France: the REMIX study

POSTER PRESENTATION

Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I

December 10, 2022
5:30-7:30 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D

**[ABSTRACT
1897](#)**

A Brazilian Real-Life Experience of Multiple Myeloma Patients: Final Results from the MMyBRAve Multi-Center Study

POSTER PRESENTATION

Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I

December 10, 2022
5:30-7:30 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D

HEMATOLOGY

ABSTRACT # TITLE SESSION

VON WILLEBRAND DISEASE

ABSTRACT
1147

Development of a Machine Learning Algorithm for Early Diagnosis of Persons with Von Willebrand Disease Using Real-World Data

POSTER PRESENTATION

Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I

December 10, 2022
5:30-7:30 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D



ABSTRACT
3516

Real-World Analysis of Healthcare Resource Utilization and Costs Among Patients Diagnosed with Von Willebrand Disease and Angiodysplasia

POSTER PRESENTATION

Health Services and Quality —Non-Malignant Conditions: Poster II

December 11, 2022
6:00-8:00 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D

HEMOPHILIA

ABSTRACT
1152

Risk of Intracranial Hemorrhage in US Patients with Hemophilia A: Real-World Retrospective Cohort Study Using the Athndataset

POSTER PRESENTATION

Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I

December 10, 2022
5:30-7:30 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D



ABSTRACT
4780

BAX 335 Hemophilia B Gene Therapy Phase 1/2 Clinical Trial: Long-Term Safety and Efficacy Follow-up

POSTER PRESENTATION

Gene Therapies: Poster III

December 12, 2022
6:00-8:00 P.M. CT

Location: Ernest N. Morial Convention Center, Hall D

For more information, please see [ASH online program](#).